µ±Ç°Î»ÖãºÊ×Ò³ > Ò©Îï·ÖÎöµÚ7°æÑ§Ï°Ö¸µ¼ÓëϰÌ⼯ ¸½´ð°¸ - ͼÎÄ
µÚÒ»Õ ҩÎï·ÖÎöÓëÒ©Æ·ÖÊÁ¿±ê×¼
Ò»¡¢»ù±¾ÒªÇó
1£®ÕÆÎÕ£ºÒ©Îï·ÖÎöµÄÐÔÖʺÍÈÎÎñ£¬Ò©Æ·µÄ¶¨ÒåºÍÌØÊâÐÔ£¬Ò©Æ·ÖÊÁ¿ºÍÎȶ¨ÐÔÑо¿µÄÄ¿ µÄÓëÄÚÈÝ£¬Ò©Æ·±ê×¼ÖÆ¶¨µÄ·½·¨ºÍÔÔò¡£
2£®ÊìϤ£ºÒ©Æ·±ê×¼£¬ÖйúÒ©µäµÄÄÚÈݺͽøÕ¹£¬Ö÷Òª¹úÍâÒ©µäµÄÄÚÈÝ¡£ 3£®Á˽⣺ҩƷÖÊÁ¿¹ÜÀí¹æ·¶£¬Ò©Æ·¼ìÑéµÄ»ù±¾³ÌÐò¡£
¶þ¡¢»ù±¾ÄÚÈÝ
±¾ÕÂÄÚÈݺ¸Ç¡¶Ò©Îï·ÖÎö¡·µÚ7°æµÄÐ÷Âۺ͵ÚÒ»ÕÂÒ©Æ·ÖÊÁ¿Ñо¿ÄÚÈÝÓëÒ©µä¸Å¿ö¡£ £¨Ò»£©»ù±¾¸ÅÄî
Ò©Îï( drugs)ÊÇÖ¸ÓÃÓÚÔ¤·À¡¢ÖÎÁÆ¡¢Õï¶ÏÈ˵ļ²²¡£¬ÓÐÄ¿µÄµØµ÷½ÚÈ˵ÄÉúÀí»úÄܲ¢¹æ¶¨ÓÐÊÊÓ¦Ö¤»òÕß¹¦ÄÜÖ÷ÖΡ¢Ó÷¨ºÍÓÃÁ¿µÄÎïÖÊ¡£
Ò©Æ·( medicinal products)ͨ³£ÊÇÖ¸ÓÉÒ©Îï¾Ò»¶¨µÄ´¦·½ºÍ¹¤ÒÕÖÆ±¸¶ø³ÉµÄÖÆ¼Á²úÆ·£¬Êǿɹ©ÁÙ´²Ê¹ÓõÄÉÌÆ·¡£Ò©Îïͨ³£±ÈÒ©Æ·±í´ï¸ü¹ãµÄÄÚº¡£
Ò©Æ·ÊÇÓÃÓÚÖβ¡¾ÈÈË¡¢±£»¤½¡¿µµÄÌØÊâÉÌÆ·£¬¾ßÓÐÒÔÏÂÌØÊâÐÔ£º¢ÙÖβ¡ÓëÖ²¡µÄË«ÖØÐÔ£»¢ÚÑϸñµÄÖÊÁ¿ÒªÇóÐÔ£»(µùÉç»á¹«¹²¸£ÀûÐÔ¡£
Ò©Îï·ÖÎö(pharmaceutical analysis)ÊÇÑо¿Ò©ÎïÖÊÁ¿¹æÂÉ¡¢·¢Õ¹Ò©ÎïÖÊÁ¿¿ØÖÆ·½·¨µÄ¿ÆÑ§¡£ Ò©Îï·ÖÎöÊÇҩѧ¿ÆÑ§µÄÖØÒª·Ö֧ѧ¿Æ£¬ÊÇҩѧÑо¿µÄÖØÒª¼¼ÊõÊֶΣ¬ÈÎÎñ¾ÍÊǶÔÒ©Îï½øÐÐÈ«ÃæµÄ·ÖÎöÑо¿£¬È·Á¢Ò©ÎïµÄÖÊÁ¿¹æÂÉ£¬½¨Á¢ºÏÀíÓÐЧµÄÒ©ÎïÖÊÁ¿¿ØÖÆ·½·¨ºÍ±ê×¼£¬±£Ö¤Ò©Æ·µÄÖÊÁ¿Îȶ¨ÓëºÇ¿Ø£¬±£ÕÏҩƷʹÓõݲȫ¡¢ÓÐЧºÍºÏÀí¡£ £¨¶þ£©Ò©Æ·±ê×¼
Ò©Æ·±ê×¼£¨Ò²Ë׳ÆÎªÒ©Æ·ÖÊÁ¿±ê×¼£©Ïµ¸ù¾ÝÒ©Îï×ÔÉíµÄÀí»¯ÓëÉúÎïÑ§ÌØÐÔ£¬°´ÕÕÅú×¼µÄÀ´Ô´¡¢´¦·½¡¢Éú²ú¹¤ÒÕ¡¢Öü²ØÔËÊäÌõ¼þµÈËùÖÆ¶¨µÄ¡¢ÓÃÒÔ¼ì²âÒ©Æ·ÖÊÁ¿ÊÇ·ñ´ïµ½ÓÃÒ©ÒªÇ󲢺âÁ¿ÆäÖÊÁ¿ÊÇ·ñÎȶ¨¾ùÒ»µÄ¼¼Êõ¹æ¶¨¡£
¹ú¼ÒÒ©Æ·±ê×¼£¬ÊÇÖ¸¹ú¼ÒʳƷҩƷ¼à¶½¹ÜÀí¾Ö( SFDA)°ä²¼µÄ¡¶ÖлªÈËÃñ¹²ºÍ¹úÒ©µä¡·¡¢Ò©Æ·×¢²á±ê×¼ºÍÆäËûÒ©Æ·±ê×¼£¬ÆäÄÚÈݰüÀ¨ÖÊÁ¿Ö¸±ê¡¢¼ìÑé·½·¨ÒÔ¼°Éú²ú¹¤Òյȼ¼ÊõÒªÇó¡£¹ú¼ÒÒ©Æ·¼à¶½¹ÜÀí²¿ÃÅ×éÖ¯Ò©µäίԱ»á£¬¸ºÔð¹ú¼ÒÒ©Æ·±ê×¼µÄÖÆ¶¨ºÍÐÞ¶©¡£¹ú¼ÒÒ©Æ·±ê×¼ÊÇÒ©Æ·Éú²ú¡¢¹©Ó¦¡¢Ê¹ÓᢼìÑéºÍÒ©Õþ¹ÜÀí²¿ÃŹ²Í¬×ñѵ퍶¨ÒÀ¾Ý¡£
Ò©Æ·±ê×¼µÄÄÚº°üÀ¨£ºÕæÎ±¼ø±ð¡¢´¿¶È¼ì²éºÍÆ·ÖÊÒªÇóÈý¸ö·½Ã棬ҩƷÔÚÕâÈý·½ÃæµÄ×Û
ºÏ±íÏÖ¾ö¶¨ÁËÒ©Æ·µÄ°²È«ÐÔ¡¢ÓÐЧÐÔºÍÖÊÁ¿¿É¿ØÐÔ¡£
¡¶ÖлªÈËÃñ¹²ºÍ¹úÒ©µä¡·¼ò³Æ¡¶ÖйúÒ©µä¡·£¬ÊÕÔØ¹ú¼ÒÒ©Æ·±ê×¼¡£ÏÖÐС¶ÖйúÒ©µä¡·2010Äê°æÓÉÒ»²¿¡¢¶þ²¿¡¢Èý²¿¼°ÆäÔö²¹±¾×é³É£¬ÄÚÈÝ·Ö±ð°üÀ¨·²Àý¡¢ÕýÎĺ͸½Â¼¡£³ýÌØ±ð×¢Ã÷°æ´ÎÍ⣬¡¶ÖйúÒ©µä¡·¾ùÖ¸ÏÖÐа档¹ú¼ÒÒ©Æ·±ê×¼ÓÉ·²ÀýÓëÕýÎļ°ÆäÒýÓõĸ½Â¼¹²Í¬¹¹³É¡£ ·²Àý( general notices)ÊÇΪÕýȷʹÓá¶ÖйúÒ©µä¡·½øÐÐÒ©Æ·ÖÊÁ¿¼ì¶¨µÄ»ù±¾ÔÔò£¬ÊǶԡ¶ÖйúÒ©µä¡·ÕýÎÄ¡¢¸½Â¼¼°ÓëÖÊÁ¿¼ì¶¨ÓйصĹ²ÐÔÎÊÌâµÄͳһ¹æ¶¨¡£ÕýÎÄ( monograph¡£)¾ÍÊÇÒ©Æ·±ê×¼¡£¸½Â¼£¨appendices£©Ö÷ÒªÊÕÔØÖÆ¼ÁͨÔò¡¢Í¨Óüì²â·½·¨ºÍÖ¸µ¼ÔÔò¡£Ö¸µ¼ÔÔòϵΪִÐÐÒ©µä¡¢¿¼²ìÒ©Æ·ÖÊÁ¿¡¢Æð²ÝÓ븴ºËÒ©Æ·±ê×¼µÈËùÖÆ¶¨µÄÖ¸µ¼ÐԹ涨¡£
Ö÷Òª¹úÍâÒ©µäÓУºÃÀ¹úÒ©µä( USP-NF)¡¢Ó¢¹úÒ©µä(BP)¡¢Å·ÖÞÒ©µä(EP)¡¢ÈÕ±¾Ò©¾Ö·½(JP)ºÍ¹ú¼ÊÒ©µä(Ph. Int.)¡£
£¨Èý£©Ò©Æ·±ê×¼ÖÆ¶¨ÓëÎȶ¨ÐÔÊÔÑé
Ò©Æ·±ê×¼Ò»¾Öƶ¨ºÍÅú×¼£¬¼´¾ßÓз¨ÂÉЧÁ¦¡£ËùÒÔ£¬Ò©Æ·±ê×¼µÄÖÆ¶¨±ØÐë¼á³Ö¡°¿ÆÑ§ÐÔ¡¢ÏȽøÐÔ¡¢¹æ·¶ÐÔºÍȨÍþÐÔ¡±µÄÔÔò¡£Æä½¨ºøµÄ·ÖÎö·½·¨Ðë²ÉÓÿÆÑ§µÄ·½·¨ºÍÖ¸±ê½øÐÐÑéÖ¤£¬ÑéÖ¤µÄÄÚÈݰüÀ¨×¨ÊôÐÔ¡¢×¼È·¶ÈÓ뾫Ãܶȡ¢ÏßÐÔÓ뷶Χ¡¢¼ì²âÏÞÓ붨Á¿ÏÞ¡¢ÄÍÓÃÐԵȡ£ Ò©Æ·Îȶ¨ÐÔÊÔÑéµÄÄ¿µÄÊÇ¿¼²ìÒ©ÎïÔÚζȡ¢Êª¶È¡¢¹âÏßµÈÒòËØµÄÓ°ÏìÏÂËæÊ±¼ä±ä»¯µÄ¹æÂÉ£¬ÎªÒ©Æ·µÄÉú²ú¡¢°ü×°¡¢Öü´æ¡¢ÔËÊäÌõ¼þÌṩ¿ÆÑ§ÒÀ¾Ý£¬Í¬Ê±Í¨¹ýÊÔÑ齨Á¢Ò©Æ·µÄÓÐЧÆÚ£¬ÒÔ±£ÕÏÓÃÒ©µÄ°²È«ÓÐЧ¡£
Îȶ¨ÐÔÊÔÑé·ÖΪӰÏìÒòËØÊÔÑé¡¢¼ÓËÙÊÔÑéÓ볤ÆÚÊÔÑé¡£Ó°ÏìÒòËØÊÔÑéÊǽ«Ò©Æ·ÖÃÓÚ¾çÁÒµÄÌõ¼þϽøÐеÄÎȶ¨ÐÔ¿¼²ì£¬·½·¨Îª¸ßÎÂÊÔÑé¡¢¸ßʪ¶ÈÊÔÑéºÍÇ¿¹âÕÕÉäÊÔÑé¡£ÆäÄ¿µÄÊÇ̽ÌÖÒ©ÎïµÄ¹ÌÓÐÎȶ¨ÐÔ¡¢Á˽âÓ°ÏìÆäÎȶ¨ÐÔµÄÒòËØ¼°¿ÉÄܵĽµ½â;¾¶Óë½µ½â²úÎï£¬ÎªÖÆ¼ÁÉú²ú¹¤ÒÕ¡¢°ü×°¡¢Öü´æÌõ¼þºÍ½¨Á¢½µ½â²úÎï·ÖÎö·½·¨Ìṩ¿ÆÑ§ÒÀ¾Ý£»¼ÓËÙÊÔÑéÊǽ«Ò©ÎïÖÃÓÚÄ£Ä⼫¶ËÆøºòÌõ¼þϽøÐеÄÎȶ¨ÐÔ¿¼²ì¡£·½·¨ÊÇÔÚζÈ40C¡À2¡æ£¬Ïà¶Ôʪ¶È75%¡À5%µÄÌõ¼þϽøÐп¼²ì¡£ÆäÄ¿µÄÊÇͨ¹ý¼ÓËÙÒ©ÎïµÄ»¯Ñ§»òÎïÀí±ä»¯£¬Ì½ÌÖÒ©ÎïµÄÎȶ¨ÐÔ£¬ÎªÖƼÁÉè¼Æ¡¢°ü×°¡¢ÔËÊä¡¢Öü´æÌṩ±ØÒªµÄ×ÊÁÏ£»³¤ÆÚÊÔÑéÊǽ«Ò©ÎïÖÃÓÚ½Ó½üʵ¼ÊÖü´æµÄÌõ¼þ£¨ÊÐÊÛ°ü×°£¬Î¶È25C+ 2aC£¬Ïà¶Ôʪ¶È600-/0¡À10%£©Ï½øÐеÄÎȶ¨ÐÔ¿¼²ì¡£ÆäÄ¿µÄÎªÖÆ¶©Ò©ÎïµÄÓÐЧÆÚÌṩÒÀ¾Ý¡£
£¨ËÄ£©Ò©Æ·¼ìÑé
Ò©Æ·¼ìÑ鹤×÷µÄ»ù±¾³ÌÐò¡«°ãΪȡÑù£¨¼ìÆ·Êռ죩¡¢¼ìÑé¡¢ÁôÑù¡¢±¨¸æ¡£È¡Ñù±ØÐë¾ßÓпÆÑ§ÐÔ¡¢ÕæÊµÐԺʹú±íÐÔ£¬È¡ÑùµÄ»ù±¾ÔÔòÓ¦¸ÃÊǾùÔÈ¡¢ºÏÀí£»³£¹æ¼ìÑéÒÔ¹ú¼ÒÒ©Æ·±ê׼ΪÒÀ¾Ý£¬°´Õչ涨·½·¨ºÍÓйØSOP½øÐмìÑ飬¸ù¾Ý¼ìÑé½á¹ûÊéд¼ìÑ鱨¸æÊé¡£¼ìÑé¼Ç¼±ØÐë
×öµ½£º¼Ç¼Ôʼ¡¢ÕæÊµ£¬ÄÚÈÝÍêÕû¡¢ÆëÈ«£¬ÊéдÇåÎú¡¢Õû½à¡£¸ù¾Ý¸÷Ïî¼ìÑé½á¹û¶Ô¼ìÆ·×÷³öÃ÷È·µÄ½áÂÛ¡£
£¨Î壩ҩƷÖÊÁ¿¹ÜÀí¹æ·¶
ΪÁËÔÚÒ©ÎïµÄÑо¿¡¢¿ª·¢¡¢Éú²ú¡¢¾Óª¡¢Ê¹Óúͼà¹ÜµÈ¸÷»·½ÚʵÐÐÈ«³ÌµÄÖÊÁ¿¸ú×ÙÓë¹ÜÀí£¬¹úÎñÔºÒ©Æ·¼à¶½¹ÜÀí²¿ÃÅ( SFDA)ÒÀ·¨Öƶ¨ÁËÏà¹ØµÄ¹ÜÀí¹æ·¶(GLP¡¢GCP¡¢GMP¡¢GSP ºÍGAPµÈ£©¡£Ê¹Ò©Æ·ÖÊÁ¿¿ØÖƺͱ£Ö¤ÒªÇó´ÓÖÊÁ¿Éè¼Æ£¨Quality by Design£©¡¢¹ý³Ì¿ØÖÆ( Quality by Process)ºÍÖն˼ìÑé(Quality by Test)Èý·½ÃæÀ´ÊµÊ©£¬±£ÕÏÓÃÒ©°²È«¡£ £¨Áù£©×¢²áÉóÅúÖÆ¶ÈÓëICH
ΪÁËе÷¸÷¹ú¶ÔÒ©Æ·µÄÉóÅú×¢²áµÄ²»Í¬ÒªÇó£¬ÓÉÅ·ÃË¡¢ÃÀ¹úºÍÈÕ±¾Èý·½µÄÒ©Æ·×¢²á¹ÜÀíµ±¾ÖºÍÖÆÒ©ÆóÒµ¹ÜÀí»ú¹¹·¢ÆðÁË¡°ÈËÓÃÒ©Æ·×¢²á¼¼ÊõÒªÇó¹ú¼Êе÷»á¡±( IntemationalConference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals forHuman Use£¬ICH£©¡£ICHµÄÄ¿µÄÊÇͨ¹ýе÷Ò»Ö£¬Ê¹Èý·½ÔÚÒ©Æ·×¢²á¼¼ÊõÒªÇóÉÏÈ¡µÃ¹²Ê¶£¬ÎªÒ©Æ·Ñз¢¡¢ÉóÅúºÍÉÏÊÐÖÆ¶¨Í³Ò»µÄ¹ú¼ÊÐÔ¼¼ÊõÖ¸µ¼ÔÔò¡£ICHе÷µÄÄÚÈݰüÀ¨Ò©Æ·ÖÊÁ¿£¨Quality£¬ÒÔ´úÂëQ±êʶ£©¡¢°²È«ÐÔ£¨Safety£¬ÒÔ´úÂëS±êʶ£©¡¢ÓÐЧÐÔ£¨Efficacy£¬ÒÔ´úÂëE±êʶ£©ºÍ×ÛºÏÒªÇó£¨Multidisciplinary£¬ÒÔ´úÂëM±êʶ£©ËÄ·½ÃæµÄ¼¼ÊõÒªÇó¡£
Èý¡¢Ï°ÌâÓë½â´ð
£¨Ò»£©×î¼ÑÑ¡ÔñÌâ
D 1£®ICHÓйØÒ©Æ·ÖÊÁ¿êÀ¼¼ÊõÒªÇóÎļþµÄ±êʶ´úÂëÊÇ A£®E B£®M C£®P D£®Q E£®S B 2£®Ò©Æ·±ê×¼Öмø±ðÊÔÑéµÄÒâÒåÔÚÓÚ
A£®¼ì²éÒÑÖªÒ©ÎïµÄ´¿¶È B£®ÑéÖ¤ÒÑÖªÒ©ÎïÓëÃû³ÆµÄÒ»ÖÂÐÔ C£®È·¶¨ÒÑÖªÒ©ÎïµÄº¬Á¿ D£®¿¼²ìÒÑÖªÒ©ÎïµÄÎȶ¨ÐÔ E£®È·Ö¤Î´ÖªÒ©ÎïµÄ½á¹¹ A 3£®ÑÎËáÈÜÒº(9¡ú1000)ϵָ
A£®ÑÎËá1.0ml¼Óˮʹ³Él000mlµÄÈÜÒº B£®ÑÎËá1. 0ml¼Ó¼×´¼Ê¹³Él000mlµÄÈÜÒº C£®ÑÎËá1. 0g¼Óˮʹ³Él000mlµÄÈÜÒº D£®ÑÎËá1. 0g¼ÓË®l000mlÖÆ³ÉµÄÈÜÒº E£®ÑÎËá1. 0ml¼ÓË®l000mlÖÆ³ÉµÄÈÜÒº
D4£®ÖйúÒ©µä·²Àý¹æ¶¨£º³ÆÈ¡¡°2. 0g¡±£¬ÏµÖ¸³ÆÈ¡ÖØÁ¿¿ÉΪ
A. 1.5 ~2.5g B. 1. 6 ~2. 4g C. 1. 45¡«2. 45g D. 1. 95 ~2. 05g E. 1. 96 - 2. 04g
D 5£®ÖйúÒ©µä¹æ¶¨£ººãÖØ£¬³ýÁíÓй涨Í⣬ϵָ¹©ÊÔÆ·Á¬ÐøÁ½´Î¸ÉÔï»ò³ãׯºóµÄÖØÁ¿²îÒìÔÚ
A. 0.0lmg B.0.03mg C.0.1mg D.0.3mg E.0.5mg
E 6£®ÔÁÏÒ©Îȶ¨ÐÔÊÔÑéµÄÓ°ÏìÒòËØÊÔÑ飬ÊèËÉÔÁÏÒ©ÔÚ¿ª¿ÚÈÝÆ÷ÖÐ̯³É±¡²ãµÄºñ¶ÈÓ¦ A. >20cm B.¡Ü20cm C.¡Ül0cm D. ¡Ü5cm E.¡Ül0mm E 7£®ÏÂÁÐÄÚÈÝÖУ¬ÊÕÔØÓÚÖйúÒ©µä¸½Â¼µÄÊÇ
A£®ÊõÓïÓë·ûºÅ B£®¼ÆÁ¿µ¥Î» C£®±ê׼ƷÓëʱÕÕÆ· D£®×¼È·¶ÈÓ뾫ÃܶÈÒªÇó E£®Í¨Óüì²â·½·¨ E 8£®ÏÂÁйØÓÚÅ·ÖÞÒ©µä(EP)µÄ˵·¨ÖУ¬²»ÕýÈ·µÄÊÇ A£®EPÔÚÅ·ÃË·¶Î§ÄÚ¾ßÓз¨ÂÉЧÁ¦ B£®EP²»ÊÕÔØÖÆ¼Á±ê×¼
C£®EPµÄÖÆ¼ÁͨÔòÖи÷ÖÆ¼ÁÏîϰüº¬£º¶¨Ò壨Definition£©¡¢Éú²ú(Production)ºÍ¼ì²é ( Test) D£®EPÖÆ¼ÁͨÔòÏîϵĹ涨Ϊָµ¼ÐÔÔÔò E£®EPÓÉWHOÆð²ÝºÍ³ö°æ £¨¶þ£©ÅäÎéÑ¡ÔñÌâ [9¡ª10]
A. SFDA B.ChP C.GCP D.GLP E.GMP ÏÂÁйÜÀí¹æ·¶µÄÓ¢ÎÄËõдÊÇ D 9£®Ý§Æ··ÇÁÙ´²Ñо¿ÖÊÁ¿¹ÜÀí¹æ·¶ E 10.Ò©Æ·Éú²úÖÊÁ¿¹ÜÀí¹æ·¶ [11¡ª13J
A£®ÈÜÖÊlg( ml)ÄÜÔÚÈܼÁ²»µ½1mlÖÐÈܽâ B£®ÈÜÖÊlg( ml)ÄÜÔÚÈܼÁ1-²»µ½l0mlÖÐÈܽâ C£®ÈÜÖÊlg( ml)ÄÜÔÚÈܼÁ10 -£®²»µ½30mlÖÐÈܽâ D£®ÈÜÖÊ1g( ml)ÄÜÔÚÈܼÁ30~²»µ½l00mlÖÐÈܽâ E£®ÈÜÖÊlg( ml)ÄÜÔÚÈܼÁ100Ò»²»µ½l000mlÖÐÈܽâ ÏÂÁÐÈܽâ¶ÈÊõÓïϵָ
¹²·ÖÏí92ƪÏà¹ØÎĵµ